A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring

被引:71
作者
Lewandowski, Robert J.
Wang, Dingxin
Gehl, James
Atassi, Bassel
Ryu, Robert K.
Sato, Kent
Nemcek, Albert A., Jr.
Miller, Frank H.
Mulcahy, Mary F.
Kulik, Laura
Larson, Andrew C.
Salem, Riad
Omary, Reed A.
机构
[1] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Biomed Engn, Chicago, IL 60611 USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
关键词
D O I
10.1016/j.jvir.2007.06.028
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: Transcatheter arterial chemoembolization (TACE) is an established treatment for unresectable liver cancer. This study was conducted to test the hypothesis that angiographic endpoints during TACE are measurable and reproducible by comparing subjective angiographic versus objective magnetic resonance (MR) endpoints of TACE. MATERIALS AND METHODS: The study included 12 consecutive patients who presented for TACE for surgically unresectable HCC or progressive hepatic metastases despite chemotherapy. All procedures were performed with a dedicated imaging system. Angiographic series before and after TACE were reviewed independently by three board-certified interventional radiologists. A subjective angiographic chemoembolization endpoint (SACE) classification scheme, modified from an established angiographic grading system in the cardiology literature, was designed to assist in reproducibly classifying angiographic endpoints. Reproducibility in SACE classification level was compared among operators, and MR imaging perfusion reduction was compared with SACE levels for each observer. RESULTS: Twelve patients successfully underwent 15 separate TACE sessions. SACE levels ranged from I through IV. There was moderate agreement in SACE classification (K = 0.46 +/- 0.12). There was no correlation between SACE level and MR perfusion reduction (r = 0.16 for one operator and 0.02 for the other two). CONCLUSIONS: Angiographic endpoints during TACE vary widely, have moderate reproducibility among operators, and do not correlate with functional MR imaging perfusion endpoints. Future research should aim to determine ideal angiographic and functional MR imaging endpoints for TACE according to outcome measures such as imaging response, pathologic response, and survival.
引用
收藏
页码:1249 / 1257
页数:9
相关论文
共 38 条
[1]   Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen) [J].
Boucher, E ;
Corbinais, S ;
Brissot, P ;
Boudjema, K ;
Raoul, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (04) :305-308
[2]   Liver resection for colorectal metastases [J].
Bramhall, SR ;
Gur, U ;
Coldham, C ;
Gunson, BK ;
Mayer, AD ;
McMaster, P ;
Candinas, D ;
Buckels, JAC ;
Mirza, DF .
ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 2003, 85 (05) :334-339
[3]   Society of interventional radiology position statement on chemoembolization of hepatic malignancies [J].
Brown, DB ;
Geschwind, JFH ;
Soulen, MC ;
Millward, SF ;
Sacks, D .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2006, 17 (02) :217-223
[4]   Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy [J].
Brown, DB ;
Cardella, JF ;
Sacks, D ;
Goldberg, SN ;
Gervais, DA ;
Rajan, D ;
Vedantham, S ;
Miller, DL ;
Brountzos, EN ;
Grassi, CJ ;
Towbin, RB .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2006, 17 (02) :225-232
[5]   Hepatic arterial chemoembolization for hepatocellular carcinoma: Comparison of survival rates with different embolic agents [J].
Brown, DB ;
Pilgram, TK ;
Darcy, MD ;
Fundakowski, CE ;
Lisker-Melman, M ;
Chapman, WC ;
Crippin, JS .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (12) :1661-1666
[6]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[7]   High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial [J].
Chow, PKH ;
Tai, BC ;
Tan, CK ;
Machin, D ;
Win, KM ;
Johnson, PJ ;
Soo, KC .
HEPATOLOGY, 2002, 36 (05) :1221-1226
[8]   PROGNOSTIC FACTORS IN PATIENTS AFFECTED BY HEPATOCELLULAR-CARCINOMA TREATED WITH SYSTEMIC CHEMOTHERAPY - THE EXPERIENCE OF THE NATIONAL-CANCER-INSTITUTE-OF-MILAN [J].
COLLEONI, M ;
BAJETTA, E ;
NELLI, P ;
BONI, L ;
BOCHICCHIO, AM ;
NOLE, F ;
BUZZONI, R ;
CELIO, L ;
MAZZAFERRO, V ;
BONFANTI, G ;
BIGNAMI, P ;
GENNARI, L .
ANNALS OF ONCOLOGY, 1993, 4 (06) :489-493
[9]   Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis [J].
Georgiades, CS ;
Hong, K ;
D'Angelo, M ;
Geschwind, JFH .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (12) :1653-1659
[10]   Transcatheter arterial chemoembolization of liver tumors: Effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency [J].
Geschwind, JFH ;
Ramsey, DE ;
Cleffken, B ;
van der Wal, BCH ;
Kobeiter, H ;
Juluru, K ;
Hartnell, GG ;
Choti, MA .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2003, 26 (02) :111-117